Expression of tumour associated antigens 12H12, 2E11, 7A9, CEA and DF3 in human breast cancer.
Expression of tumour associated antigens 12H12, 2E11, 7A9, CEA and DF3 was determined immunohistochemically in paraffin embedded biopsy specimens from 42 breast carcinomas. The mean (SD) of staining index (I) for 12H12 was 0.95(0.94), for 2E11 1.30(0.99), for FA9 1.11(0.92), for CEA 0.03(0.1) and for DF3 1.32(0.93). Of the 42 carcinomas, 3 (7.1%) were totally negative for 12H12, 3/42 (7.1%) for 2E11, 6/42 (14.3%) for 7A9, 34/42 (81%) for CEA and 6/45 (13.3%) for DF3. The 12H12 positivity was related significantly to axillary lymph node status (r = 0.41, p < 0.01), expression of 7A9 (r = 0.71, p < 0.001), expression of 2E11 (r = 0.76, p < 0.001), expression of DF3 (r = 0.40, p < 0.01) and TPA serum level (r = 0.41, p < 0.01). The 2E11 positivity was related to axillary lymph node status (r = 0.43, p < 0.01), expression of 7A9 (r = 0.95, p < 0.001) and 12H12 (r = 0.76, p < 0.001). The 7A9 positivity was related to axillary lymph node status (r = 0.44, p < 0.01), expression of 7A9 (r = 0.71, p < 0.001), 12H12 (r = 0.71, p < 0.001) and 2E11 (r = 0.95, p < 0.001). The DF3 positivity was significantly related to expression of 12H12 (r = 0.40, p < 0.01). The CEA positivity was not significantly related to any of the tested variables. The results suggest that antigens 12H12, 2E11 and 7A9 should be subject to further analysis in breast cancer research. Particularly, they may be helpful in separating benign breast lesions from the more malignant ones. Secondly, the relationship between high expression of the antigens and axillary lymph node status suggests that these antigens may have also prognostic value.
Eskelinen
M
M
Department of Surgery, University of Kuopio, Finland.
Lipponen
P
P
Hippeläinen
M
M
Seveus
L
L
Syrajänen
K
K
D000951:Antigens, Neoplasm / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001940:Breast / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D005260:Female; D006801:Humans
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen